Alessandra Bettiol, Maria Letizia Urban, Roberto Padoan, Matthieu Groh, Giuseppe Lopalco, Allyson Egan, Vincent Cottin, Paolo Fraticelli, Claudia Crimi, Stefano Del Giacco, Laura Losappio, Laura Moi, Francesco Cinetto, Marco Caminati, Pavel Novikov, Alvise Berti, Paolo Cameli, Pascal Cathébras, Angelo Coppola, Cécile-Audrey Durel, Marco Folci, Alberto Lo Gullo, Carlo Lombardi, Sara Monti, Paola Parronchi, Carlos Martinez Rivera, Roser Solans, Angelo Vacca, Georgina Espígol-Frigolé, Gabriella Guarnieri, Fulvia Chieco Bianchi, Maria Rita Marchi, Colas Tcherakian, Jean-Emmanuel Kahn, Florenzo Iannone, Vincenzo Venerito, Charlene Desaintjean, Gianluca Moroncini, Santi Nolasco, Giulia Anna Maria Luigia Costanzo, Jan Walter Schroeder, Camillo Ribi, Michelangelo Tesi, Elena Gelain, Irene Mattioli, Federica Bello, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi
BACKGROUND: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients with EGPA. METHODS: This retrospective cohort study included patients with EGPA from 28 European referral centres of the European EGPA Study Group across six countries (Italy, France, UK, Russia, Spain, and Switzerland) who received benralizumab as any line of treatment between Jan 1, 2019, and Sep 30, 2022...
December 2023: Lancet Rheumatology